Summary

How BDY maps according to Revere

Sector Level Count
Industries 2
Sectors 3
Subsectors 10
Product/Service Groups 31

Specific product example for BDY

Product Hierarchy
Consumer
Consumer Products and Services
Personal Care and Cleaning Products
Cosmetics

Company Highlights:

Market Cap. 339.062
Current Shares Outstnd. 17.0
Contact Name Cecelia C. Heer
Contact Phone (973)8821505
City, State Fairfield, NJ
Dividends Per Common Share 0.00
Dividend Yield n/a
SI %SHOUT 5.42
IH % Shares Outst. n/a
Number of Employees 300
Revenue Per Employee 448,602.4
Book Value Per Share 11.34
5 Year CAGR in Revenues % 41.31
5 Year CAGR in Earnings % 9.33
Asset Turnover 0.14
Fiscal Year End 12/31/2007
Next Reporting Period Dec, 2007

Business Description:

Bradley Pharmaceuticals, Inc. is a specialty pharmaceutical company that acquires, develops and markets prescription and over-the-counter products in niche therapeutic markets, including dermatology, podiatry, gastroenterology and women?s health. The Company has two primary business segments, its Doak Dermatologics subsidiary (which includes the products acquired from Bioglan Pharmaceuticals), specializing in therapies for dermatology and podiatry, and its Kenwood Therapeutics division, providing gastroenterology, women?s health, respiratory and other internal medicine brands. To a lesser extent, Kenwood Therapeutics also markets nutritional supplements and respiratory products. During the year ended December 31, 2006, the Company launched its A. Aarons subsidiary, which markets authorized generic versions of Doak?s and Kenwood?s products. In February 2008, the Company was acquired by Nycomed US Inc., a unit of Swiss pharmaceutical company, Nycomed.

Chart:

Last Price 20.00
Price Chg. 0.00
Price Chg. % 0.00%
Open Price n/a
High Price n/a
Low Price n/a
52w High Price 23.38
52w Low Price 14.06
Volume 0
30d Avg. Volume 211,969
BDY - Chart
* Quotes delayed 20 minutes.

Products

Products Manufactured/Services Performed Details
Consumer
Consumer Products and Services
Personal Care and Cleaning Products
Cosmetics

Products:

  • Doak Dermatologics Tx Systems
Skin Care

Products:

  • Doak Dermatologics PrameGel
  • Doak Dermatologics A-Fil Cream
  • Doak Dermatologics A'Mantle
  • Doak Dermatologics Formula 405
Healthcare
Biopharmaceuticals
Allergies
Upper Respiratory
Antihistamines/Decongestants

Products:

  • Kenwood Therapeutics Deconamine/Deconamine SR (Chlorpheniramine/Pseudoephedrine)
Dermatology
Acne
Vulgaris
Antibacterial Agents
Tetracyclines

Products:

  • Adoxa Pak (Doxycycline Monohydrate)
  • Adoxa (Doxycycline Monohydrate)
Keratolytic Agents

Products:

  • Doak Dermatologics Zoderm
  • Doak Dermatologics BenzaShave 5% And 10% (Benzoyl Peroxide)
  • Doak Dermatologics Zoderm Redi-Pads (Benzoyl Peroxide)
Lesion/Scaling Disorders
Actinic Keratoses
Non-Steroidal Anti-Inflammatory Drugs (NSAID)
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)

Products:

  • Solaraze Gel (Diclofenac Sodium)
Dermatitis
Atopic (Eczema)
Emollients

Products:

  • Doak Dermatologics Kerol Redi-Cloths/Kerol Topical Suspension (Urea/Lactic Acid)
  • Doak Dermatologics Keralac Nailstik/Nail Gel (50% Urea)
  • Doak Dermatologics Keralac Ointment (50% Urea)
  • Doak Dermatologics Keralac Cream/Lotion (50%/35% Urea)
  • Doak Dermatologics Doak Carmol 20
  • Doak Dermatologics Doak Carmol 10
  • Doak Dermatologics Doak DPM-Cream (Urea)
  • Doak Dermatologics Doak Carmol 40 (Urea)
  • Doak Dermatologics Doak Tar Lotion/Oil
Seborrheic (Dandruff)
Antifungal Agents
Imidazoles

Products:

  • Doak Dermatologics Selseb (Selenium Sulfide)
Coal Tar

Products:

  • Doak Dermatologics Doak Tar Shampoo
Keratolytic Agents

Products:

  • Doak Dermatologics Doak TransVerSal (Salicyclic Acid)
Para Aminobenzoic Acid (PABA) Inhibitors

Products:

  • Doak Dermatologics Doak Rosula Aqueous Cleanser/Gel/Medicated Pads (Sodium Sulfacetamide/Sulfur/Urea)
  • Tersaseptic
  • Doak Dermatologics Doak Carmol Scalp Treatment (Sulfacetamide Sodium)
Dermatoses
Steroidal Anti-Inflammatory Drugs (SAID)/Blood Plasma Osmolality Increasing Agents

Products:

  • Doak Dermatologics Doak Carmol HC (Hydrocortisone Acetate/Urea)
Ichthyosis
Emollients

Products:

  • Doak Dermatologics Keralac Ointment (50% Urea)
  • Doak Dermatologics Keralac Cream/Lotion (50%/35% Urea)
Lactic Acid Compounds

Products:

  • Doak Dermatologics Kerol Redi-Cloths/Kerol Topical Suspension (Urea/Lactic Acid)
Pruritus
Tricyclic Compounds

Products:

  • Zonalon Cream (Doxepin Hydrochloride)
Psoriasis
Keratolytic Agents

Products:

  • Doak Dermatologics Doak TransVerSal (Salicyclic Acid)
Digestive System
Gastrointestinal Tract Disorders
Gastroduodenal Disorders
Peptic Ulcers
Duodenal
Anticholinergic Agents

Products:

  • Kenwood Therapeutics Pamine (Methscopolamine Bromide)
  • Kenwood Therapeutics Pamine Forte (Methscopolamine Bromide)
  • A. Aarons Methscopolamine Bromide
Gastric
Anticholinergic Agents

Products:

  • A. Aarons Methscopolamine Bromide
  • Kenwood Therapeutics Pamine (Methscopolamine Bromide)
  • Kenwood Therapeutics Pamine Forte (Methscopolamine Bromide)
Intestinal Disorders
Irritable Bowel Syndrome (IBS)
Anticholinergic Agents

Products:

  • Kenwood Therapeutics Pamine (Methscopolamine Bromide)
  • A. Aarons Methscopolamine Bromide
  • Kenwood Therapeutics Pamine Forte (Methscopolamine Bromide)
Rectal Disorders
Hemorrhoids
Steroidal Anti-Inflammatory Drugs (SAID)/Sodium Channel Blocking Agents

Products:

  • Kenwood Therapeutics AnaMantle HC (Lidocaine/Hydrocortisone Acetate)
  • Kenwood Therapeutics Peranex HC Cream (Lidocaine/Hydrocortisone Acetate)
Endocrinology/Metabolism
Reproductive Disorders
Menopause
Estrogens

Products:

  • Elestrin (Estradiol Gel)
Infectious Diseases
Bacterial
Antibacterial Agents
Broad Spectrum
Antibiotics
Tetracyclines

Products:

  • Adoxa (Doxycycline Monohydrate)
  • Adoxa Pak (Doxycycline Monohydrate)
Protozoal
Antiprotozoal Agents
Broad Spectrum
Tetracyclines

Products:

  • Adoxa Pak (Doxycycline Monohydrate)
  • Adoxa (Doxycycline Monohydrate)
Viral
DNA Viruses
Papillomavirus
Genital Warts
Catechins

Products:

  • Veregen
  • Veregen Ointment (Sinecatechins)
  • Polyphenon E Ointment (Kunecatechins)
Obstetrics/Gynecology
Female Genital Disorders
Vulvovaginal
Dryness
Lubricants

Products:

  • Kenwood Therapeutics Lubrin
Pain Management
Anesthesia
Local
Sodium Channel Blocking Agents

Products:

  • Doak Dermatologics Doak Carmol Scalp Treatment (Sulfacetamide Sodium)
  • Doak Dermatologics Doak LidaMantle/LidaMantle HC
Respiratory System
Upper Respiratory Tract Disorders
Coughs/Colds
Antihistamines/Decongestants

Products:

  • Kenwood Therapeutics Deconamine/Deconamine SR (Chlorpheniramine/Pseudoephedrine)
Decongestants

Products:

  • Kenwood Therapeutics Tyzine (Tetrahydrozoline)
Expectorants/Opioids

Products:

  • Kenwood Therapeutics Brontex (Codeine Phosphate/Guaifenesin)
Nasal Dryness
Moisturizing Agents

Products:

  • Kenwood Therapeutics Entsol
Nutritional Health
Dietary/Naturopathic Supplements
General Health

Products:

  • Kenwood Therapeutics

Key Financials

FY Ends September
Period Length/End 3 months
ending
09/30/2007 		3 months
ending
06/30/2007 		3 months
ending
09/30/2006 		12 months
ending
12/31/2006 		12 months
ending
12/31/2005 		12 months
ending
12/31/2004
Total Revenue 33.6 32.2 35.2 144.8 133.4 96.7
Gross Margin % 81.3 79.24 83.74 84.51 85.14 86.2
Operating Income -2.4 -3.0 6.5 16.7 13.0 13.1
Operating Margin % -7.29 -9.32 18.55 11.56 9.75 13.51
Tax Rate % 49.35 44.16 42 42.22 38.8 39.1
Income After Taxes -1.2 -1.7 3.8 9.7 8.0 8.0
Net Income Margin % -3.69 -5.2 10.76 6.68 5.97 8.23
F.D. EPS - Incl. Xord. Items -0.07 -0.10 0.23 0.58 0.49 0.49
Book Value Per Share 11.34 11.37 10.63 11.36 10.53 10.25

Ratios

P/R Ratio (TTM) 2.40
P/E Ratio (TTM) 466.29
Price To Free Cash Flow (TTM) 251.30
Price To Book Value 1.76
Net Assets to Market Cap. % 16.57%
Beta 1.90
Days to Sell Inventory 144.3
Current Ratio 1.14
Quick Ratio 0.52
Interest Coverage 1
Debt to Market Cap. % 0.00%
Return on Equity % 0.38
Return on Assets % 0.3
Return on Invested Capital % 0.38

Major Competitors

Name Trailing Revenue P/R Ratio (TTM) P/E Ratio (TTM) 1 Year Return % Overlap
Axcan Pharma Inc. (USA) 363.0 3.56 16.94 46.61% 2
Barrier Therapeutics, Inc. 17.4 7.33 0.00 -44.44% 1
CollaGenex Pharmaceutical, Inc 59.8 5.86 0.00 20.71% 0
Graceway Pharmaceuticals, LLC n/a n/a n/a n/a 0
King Pharmaceuticals, Inc. 2,136.9 1.22 14.25 -43.16% 1
Medicis Pharmaceutical Corporation 464.7 2.48 15.38 -43.59% 5
Salix Pharmaceuticals, Ltd. 258.9 1.24 7.81 -52.50% 0
Sciele Pharma Inc. 382.3 1.93 16.25 -10.00% 2
Stiefel Laboratories, Inc. n/a n/a n/a n/a 1
Valeant Pharmaceuticals International 892.0 1.40 0.00 -23.31% 1
Wyeth 22,399.8 2.61 12.65 -10.87% 5
Average 2,997.2 3.07 9.25 -17.84% 2

Customers

Name Last Quarter Financial Stats 1 YR Price Performance %
Y/Y Revenue Growth % Sequential Revenue Growth % Y/Y Margin Growth % Sequential Margin Growth %
AmerisourceBergen Corp. 3.87 5.99 -10.12 1.63 -20.68%
Cardinal Health, Inc. 6.88 5.96 -5.10 0.04 -15.65%
McKesson Corporation 14.64 8.36 -22.64 -27.51 5.46%
Quality King Distributors n/a n/a n/a n/a n/a
Average 8.46 6.77 -12.62 -8.61 -10.29%

Notes:

Strategic Partners

Name Subtypes 1 YR Price Performance %
AmerisourceBergen Corp. Distribution -20.68%
BioSante Pharmaceuticals, Inc. In-licensing -21.05%
Cardinal Health, Inc. Distribution, Supplier -15.65%
DPT Laboratories, Ltd. Manufacturing n/a
Groupe PARIMA, Inc. Supplier n/a
Marine Polymer Technologies, Inc.   n/a
McKesson Corporation Distribution 5.46%
Par Pharmaceutical Companies, Inc. Distribution, Out-licensing -27.14%
Quality King Distributors Distribution n/a
sanofi-aventis (ADR) Distribution, Marketing -12.54%

Business/Geographical Segments

Business Segments

Source:  10-Q Nov 08, 2007
  External Revenue Total Revenue Depreciation Income Before Tax Pre-Tax Margin (%) Income Tax - Total Income After Tax Net Profit Margin (%) Total Assets
Doak Dermatologics, Inc. 26.0 77.4% 26.0 77.4% 2.4 84.0% 0.1 -3.1% 0.30% 0.3 -23.4% -0.2 16.6% -0.79% 178.5 74.0%
Kenwood Therapeutics 6.2 18.5% 6.2 18.5% 0.5 16.0% -2.6 105.8% -41.78% -1.5 127.1% -1.1 85.1% -17.02% 16.5 6.8%
A.Aarons 1.4 4.1% 1.4 4.1%     0.1 -2.7% 4.76% 0.0 -3.6% 0.0 -1.8% 1.59% 1.3 0.5%
Bioglan Pharmaceuticals Corp.                             45.1 18.7%
Segment Total 33.6 100.0% 33.6 100.0% 2.9 100.0% -2.4 100.0% -7.29% -1.2 100.0% -1.2 100.0% -3.69% 241.4 100.0%
Consolidated Total 33.6   33.6   2.9   -2.4   -7.29% -1.2   -1.2   -3.69% 241.4  

Geographic Segments

Source:  10-Q Nov 08, 2007
  External Revenue Total Revenue
United States 31.4 97.5% 31.4 97.5%
Other Countries 0.8 2.5% 0.8 2.5%
Segment Total 32.2 100.0% 32.2 100.0%
Consolidated Total 32.2   32.2